Notice: This company has been marked as potentially delisted and may not be actively trading. Alterity Therapeutics (PRAN) News Today Add Compare Share Share Headlines Stock AnalysisCompetitorsHeadlinesTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Alterity CEO says ‘filled with optimism for 2025’January 10, 2025 | markets.businessinsider.comAlterity Therapeutics Alerts Investors on Potential RisksNovember 23, 2024 | markets.businessinsider.comAlterity Therapeutics Advances Amid Successful AGMNovember 22, 2024 | markets.businessinsider.comAlterity Therapeutics Advances in Neurodegenerative Drug TrialsNovember 21, 2024 | markets.businessinsider.comAlterity Therapeutics Appoints New Company SecretaryNovember 19, 2024 | markets.businessinsider.comAlterity Therapeutics appoints Abby Macnish Niven as secretaryNovember 19, 2024 | markets.businessinsider.comAlterity Therapeutics Unveils New Advances for MSA TrackingNovember 12, 2024 | markets.businessinsider.comAlterity Therapeutics announces new publication on ATH434November 6, 2024 | markets.businessinsider.comAlterity Therapeutics: Innovative Approach with ATH434November 6, 2024 | markets.businessinsider.comAlterity Therapeutics Reveals Positive MSA Trial DataOctober 31, 2024 | markets.businessinsider.comAlterity Therapeutics Prepares for 2024 Annual General MeetingOctober 23, 2024 | markets.businessinsider.comAlterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®October 2, 2024 | markets.businessinsider.comAlterity Therapeutics Appoints Abby Macnish Niven To Succeed Phillip Hains As CFOSeptember 30, 2024 | markets.businessinsider.com‘Holy Grail’ – Alterity Therapeutics aims to slow progression of Parkinson’s diseaseSeptember 18, 2024 | msn.comKazia Therapeutics Limited (KZIA)April 18, 2024 | finance.yahoo.comAlterity Therapeutics Says Phillip Hains To Replace Kathryn Andrews As CFODecember 21, 2023 | nasdaq.comAlterity Therapeutics Appoints Phillip Hains as Chief Financial OfficerDecember 21, 2023 | markets.businessinsider.comAlterity jumps after promising data on Parkinson's candidateDecember 4, 2023 | seekingalpha.comWhy Is Alterity Therapeutics (ATHE) Stock Up 150% Today?December 4, 2023 | investorplace.comAxsome Therapeutics Inc AXSMOctober 31, 2023 | morningstar.comADRs End Higher; Orchard Therapeutics PLC Climbs 96%October 8, 2023 | morningstar.comAlterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson's and Alzheimer'sAugust 23, 2023 | technews.tmcnet.comAlterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer's DiseaseMarch 14, 2023 | technews.tmcnet.comAlterity: Study Shows ATH434 Prevents Loss of Brain Cells in Parkinson's Disease Animal ModelJanuary 30, 2023 | marketwatch.comAlterity Therapeutics Stock (OTC:PRNAF), Analyst Ratings, Price Targets, PredictionsSeptember 26, 2022 | benzinga.comHere's Why Alterity Therapeutics Shares Are VolatileSeptember 20, 2022 | msn.com Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Email Address PRAN Media Mentions By Week PRAN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRAN News Sentiment▼0.000.63▲Average Medical News Sentiment PRAN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRAN Articles This Week▼00▲PRAN Articles Average Week Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XBiotech News Today Inventiva News Today Renovaro News Today Enanta Pharmaceuticals News Today Nuvectis Pharma News Today Milestone Pharmaceuticals News Today IGM Biosciences News Today Atossa Therapeutics News Today Leap Therapeutics News Today 23andMe News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRAN) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
